Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 47 Published: June 30, 2022 Report Code: GDGMDHC22121TDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech.org

The histamine H4 receptor (HRH4) modulates eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

The HRH4 pipeline market research report provides comprehensive information on the HRH4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, the latest news as well as press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Therapy Areas in the HRH4 Pipeline Products Market

The key therapy areas in the HRH4 pipeline products market are dermatology, ear nose throat disorders, immunology, ophthalmology, and respiratory.

HRH4 Pipeline Products Market Analysis by Therapy Areas

HRH4 Pipeline Products Market Analysis by Therapy Areas

For more therapy area insights, download a free report sample

Key Mechanisms of Action in the HRH4 Pipeline Products Market

The key mechanisms of action in the HRH4 pipeline products market are Histamine H4 Receptor Antagonist and Histamine H4 Receptor Agonist.

HRH4 Pipeline Products Market Analysis by Mechanisms of Action

HRH4 Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the HRH4 Pipeline Products Market

The key routes of administration in the HRH4 pipeline products market are oral and parenteral.

HRH4 Pipeline Products Market Analysis by Routes of Administration

HRH4 Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the HRH4 Pipeline Products Market

The key molecule type in the HRH4 pipeline products market is small molecule.

Major Companies in the HRH4 Pipeline Products Market

The major companies in the HRH4 pipeline products market are Bioprojet SCR, H4Orphan Pharma, JW Pharmaceutical Corp, Leo Pharma AS, Sensorion SA, and Sosei Group Corp.

HRH4 Pipeline Products Market Analysis by Companies

HRH4 Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

HRH4 Pipeline Products Market Report Overview

Key Therapy Areas Dermatology, Ear Nose Throat Disorders, Immunology, Ophthalmology, and Respiratory
Key Mechanisms of Action Histamine H4 Receptor Antagonist and Histamine H4 Receptor Agonist
Key Routes of Administration Oral and Parenteral
Key Molecule Type Small Molecule
Major Companies Bioprojet SCR, H4Orphan Pharma, JW Pharmaceutical Corp, Leo Pharma AS, Sensorion SA, and Sosei Group Corp

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

Bioprojet SCR

H4Orphan Pharma

JW Pharmaceutical Corp

Leo Pharma AS

Sensorion SA

Sosei Group Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Overview

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Companies Involved in Therapeutics Development

Bioprojet SCR

H4Orphan Pharma

JW Pharmaceutical Corp

Leo Pharma AS

Sensorion SA

Sosei Group Corp

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Drug Profiles

azasetron – Drug Profile

Product Description

Mechanism Of Action

History of Events

BPI-7881A – Drug Profile

Product Description

Mechanism Of Action

H4 antagonist – Drug Profile

Product Description

Mechanism Of Action

History of Events

JWP-1601 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LEO-152020 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Agonize HRH4 for Idiopathic Pulmonary Fibrosis – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Antagonize Histamine 4 Receptor for Age Related Macular Degeneration and Allergic Conjunctivitis – Drug Profile

Product Description

Mechanism Of Action

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Dormant Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Discontinued Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) – Product Development Milestones

Featured News & Press Releases

Jun 15, 2022: Sensorion to present at the Inner Ear Disorder Therapeutics Summit in June 2022

Jun 07, 2022: Sensorion announces approval in France to initiate proof of concept clinical trial of SENS-401 for residual hearing preservation during cochlear implantation

Mar 17, 2022: Sensorion update on SENS-401

Feb 03, 2022: Sensorion to present three posters on SENS-401 in Cisplatin ototoxicity models at the association for research in Otolaryngology (ARO) 45th Annual MidWinter Meeting

Jan 18, 2022: Sensorion’s sudden sensorineural hearing loss asset fails Phase II test

Dec 14, 2021: LEO Pharma initiates a phase 2b dose-ranging clinical trial with an oral H4R antagonist in adult patients with moderate-to-severe atopic dermatitis (AD)

Oct 27, 2021: Sensorion surpasses enrollment target for SENS-401 in SSNHL, results available in January 2022

Oct 07, 2021: Sensorion hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021

Sep 24, 2021: Regulators approve Sensorion’s amendment to phase 2 AUDIBLE-S trial of SENS-401 in sudden sensorineural hearing loss

Sep 08, 2021: Sensorion and Cochlear to begin first clinical trial of SENS-401 for hearing preservation in combination with Cochlear Implantation

May 04, 2021: Sensorion to attend three conferences in May 2021 including ASGCT to present a poster and co-chair a scientific session

Feb 19, 2021: Sensorion presents new preclinical data on on SENS-401 at ARO 2021

Jan 19, 2021: Sensorion announces preclinical data demonstrating SENS-401’s potential to preserve residual hearing after cochlear implantation

Jan 05, 2021: Sensorion provides an update on plans and progress in the development of SENS-401 for the prevention of hearing loss

Jul 16, 2020: Sensorion hosting key opinion leader call with Dr. Michael Hoffer on sudden sensorineural hearing loss and SENS-401 as a Potential Treatment Option on July 23, 2020

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Bioprojet SCR, 2022

Pipeline by H4Orphan Pharma, 2022

Pipeline by JW Pharmaceutical Corp, 2022

Pipeline by Leo Pharma AS, 2022

Pipeline by Sensorion SA, 2022

Pipeline by Sosei Group Corp, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Frequently Asked Questions

The key therapy areas in the HRH4 pipeline products market are dermatology, ear nose throat disorders, immunology, ophthalmology, and respiratory.

The key mechanisms of action in the HRH4 pipeline products market are Histamine H4 Receptor Antagonist and Histamine H4 Receptor Agonist.

The key routes of administration in the HRH4 pipeline products market are oral and parenteral.

The key molecule type in the HRH4 pipeline products market is small molecule.

The major companies in the HRH4 pipeline products market are Bioprojet SCR, H4Orphan Pharma, JW Pharmaceutical Corp, Leo Pharma AS, Sensorion SA, and Sosei Group Corp.

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.